The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
Recruiting · NCT05502523 · Interventional (participants receive a specific treatment) · Lead sponsor: Thomas Jefferson University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.
Who can take part
Inclusion criteria
- Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
- Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease
Exclusion criteria
- Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
- Preoperative chemotherapy, immunotherapy, or radiation therapy
- Receipt of perioperative blood transfusion
Where it is running
4 locations listed across 1 US state.
- Abington Memorial Hospital - Abington, Pennsylvania, United States
- Jefferson Health Northeast - Philadelphia, Pennsylvania, United States
- Thomas Jefferson University Hospital - Philadelphia, Pennsylvania, United States
- Asplundh Cancer Pavilion at Jefferson Health - Willow Grove, Pennsylvania, United States